Search results for "Cardia"

showing 10 items of 2767 documents

Association of transcatheter direct mitral annuloplasty with acute anatomic, haemodynamic, and clinical outcomes in severe mitral valve regurgitation.

2020

Abstract Aims Several approaches for transcatheter mitral valve repair for functional mitral valve regurgitation are established. Interventional direct annuloplasty is a novel trans‐venous, trans‐septal approach. While feasibility was proven recently, knowledge on its influence on cardiac dimensions, pressures, biomarkers, and clinical outcomes is sparse. Methods and results Patients consecutively treated with direct annuloplasty‐only procedures between December 2015 and April 2018 were included in this monocentric analysis. Echocardiographic measurements, biomarker levels, clinical status [New York Heart Association (NYHA) class and 6 min walk test] were assessed at baseline, at discharge,…

medicine.medical_specialtymedicine.medical_treatmentHemodynamicsIntracardiac pressureHeart failure030204 cardiovascular system & hematologyMultidisciplinary heart team03 medical and health sciences0302 clinical medicineInternal medicineOriginal Research ArticlesMedicineDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleDiminutionMitral valve repairbiologybusiness.industrymedicine.diseaseTroponinMitral valve diseaseTranscatheter direct annuloplastyHeart failureRC666-701biology.proteinCardiologyBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessMitral valve regurgitationMitral valve repairESC heart failureReferences
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

No difference in 30-day outcome and quality of life in transradial versus transfemoral access – results from the German Austrian ABSORB registry (GAB…

2021

Abstract Background Radial (RA) instead of femoral access (FA) for coronary interventions has become a European Society of Cardiology Class-IA guideline recommendation. But when the decision on the access site is left to the discretion of the operator, differences in adverse event rates mitigate. Methods We compared the 30-day outcome for RA and FA in all patients recruited for the observational German Austrian ABSORB Registry (GABI-R) in regard to all-cause mortality, stroke, myocardial infarction (MI), TIMI major bleedings (TMB) and quality of life (QoL). All patients were treated with a bioresorbable vascular scaffold. Access site was left to the discretion of the operator. Results In to…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionHemorrhagePercutaneous Coronary InterventionQuality of lifemedicineHumansMyocardial infarctionRegistriesStrokebusiness.industryPercutaneous coronary interventionGeneral MedicineGuidelinemedicine.diseaseFemoral ArteryStrokeTreatment OutcomeAustriaEmergency medicineCohortConventional PCIRadial ArteryQuality of LifeCardiology and Cardiovascular MedicinebusinessTIMI
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct

The QRS narrowing index for easy and early identification of responder to cardiac resynchronization therapy.

2013

The rationale for cardiac resynchronization therapy (CRT) in patients with heart failure (HF) is based on the possibility of inducing substantial left ventricular reverse remodeling. It is well known that some of these patients don't benefit from this therapy (the so-called non-responders) [1,2]. No better predictors of a positive answer to CRT than pre-CRT QRS duration (QRSd) were found [3,4]. The aim of our study was to identify a parameter for an easy and early identification of responders to CRT. In this regard, according to Rickard et al., we identified and observed QRS index (QI), as an expression of electrical remodeling after CRT, and its relation with anatomic reverse remodeling, e…

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiac resynchronization therapyCardiac Resynchronization TherapyElectrocardiographyQRS complexPredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseaseseducationHeart Failureeducation.field_of_studyIschemic cardiomyopathyEjection fractionVentricular RemodelingLeft bundle branch blockbusiness.industryAtrial fibrillationRight bundle branch blockmedicine.diseaseCardiac resynchronization therapy Heart failure ResponderTreatment OutcomeMultivariate Analysiscardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiology
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Multivessel Intervention in Myocardial Infarction with Cardiogenic Shock: CULPRIT-SHOCK Trial Outcomes in the PL-ACS Registry

2021

Background: The aim of the study was a comparison of culprit-lesion-only (CL-PCI) with the multivessel percutaneous coronary intervention (MV-PCI) in terms of 30-day and 12-month mortality in a national registry. Methods: Patients from the PL-ACS registry with MI and CS were analyzed. Patients meeting the criteria of the CULPRIT-SHOCK trial were divided into two groups: CL-PCI and MV-PCI groups. Results: Of the 3265 patients in the PL-ACS registry with MI complicated by CS, the criteria of the CULPRIT-SHOCK trial were met by 2084 patients (63.8%). The CL-PCI was performed in 883 patients, and MV-PCI was performed in 1045 patients. After the propensity score matching analysis, 617 well-match…

medicine.medical_specialtymedicine.medical_treatmentacute myocardial infarction030204 cardiovascular system & hematologyRevascularizationacute myocardial infarction; cardiogenic shock; percutaneous coronary interventionCulpritArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinecardiovascular diseases030212 general & internal medicineMyocardial infarctionbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseasesurgical procedures operativemedicine.anatomical_structureShock (circulatory)Propensity score matchingMedicinemedicine.symptombusinessArteryJournal of Clinical Medicine
researchProduct

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

2021

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open sur…

medicine.medical_specialtymedicine.medical_treatmentaortic valve stenosis030204 cardiovascular system & hematologyTAVRnew-generation trans-catheter heart valvesProsthesisArticle03 medical and health sciences0302 clinical medicineValve replacementInternal medicinemedicine030212 general & internal medicineMyocardial infarctionStrokeEjection fractionbusiness.industryRGeneral Medicinemedicine.diseaseStenosisAortic valve stenosisCardiologyMedicineImplantbusinesslong-term outcomesJournal of Clinical Medicine
researchProduct

Re-interpreting complex atrial tachycardia maps using global atrial vectors.

2021

Activation maps of scar-related atrial tachycardias (AT) can be challenging to interpret due to difficulty in inaccurate annotation of electrograms, and an arbitrarily predefined mapping window. A novel mapping software integrating vector data and applying an algorithmic solution taking into consideration global activation pattern has been recently described (Coherent™, Biosense Webster "Investigational").We aimed to assess the investigational algorithm to determine the mechanism of AT compared with the standard algorithm.This study included patients who underwent ablation of scar-related AT using the Carto 3 and the standard activation algorithm. The mapping data were analyzed retrospectiv…

medicine.medical_specialtymedicine.medical_treatmenteducation030204 cardiovascular system & hematologyArticleCicatrix03 medical and health sciences0302 clinical medicineTachycardiaPhysiology (medical)Internal medicineTachycardia SupraventricularMedicineHumansIn patientProspective Studiescardiovascular diseases030212 general & internal medicineHeart AtriaAtrial tachycardiaRetrospective Studiesbusiness.industryfood and beveragesAtrial fibrillationmedicine.diseaseAblationCatheter Ablationcardiovascular systemCardiologymedicine.symptomElectrophysiologic Techniques CardiacCardiology and Cardiovascular MedicinebusinessAlgorithmsJournal of cardiovascular electrophysiologyREFERENCES
researchProduct